| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
153 |
| Employees |
98 |
| Revenues (TTM) (Millions $) |
3 |
| Net Income (TTM) (Millions $) |
-19 |
| Cash Flow (TTM) (Millions $) |
-8 |
| Capital Exp. (TTM) (Millions $) |
4 |
Business Description
Gamida Cell Ltd is a biotechnology company that specializes in the development of cell therapies for the treatment of various diseases, particularly cancer and rare genetic disorders. The company is known for its innovative approach to cell therapy, utilizing proprietary technologies to enhance the therapeutic potential of cells.
Gamida Cell's lead product candidate is called NiCord, which is being developed as a treatment for patients in need of a bone marrow transplant. NiCord is derived from umbilical cord blood and is designed to improve the availability and effectiveness of transplants for patients with hematologic malignancies and blood disorders.
The company also has a pipeline of other cell therapies in development, targeting different therapeutic areas such as solid tumors and genetic disorders. Gamida Cell's technologies aim to improve the engraftment and durability of cell therapies, offering potential advancements in the field of regenerative medicine.
Headquartered in Jerusalem, Israel, Gamida Cell collaborates with various partners, including pharmaceutical companies and research institutions, to advance its pipeline and broaden its reach in the global biotech industry.
Company Address: 116 Huntington Avenue Boston 2116 MA
Company Phone Number: 892-9080 Stock Exchange / Ticker: NASDAQ GMDA
|
%
2.09% 